GlassScriptPhysician profile
William M Johnson
NPI 1932178548
$17,728.92
in general payments reported to CMS, 2019-2025
35 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,786 · 2022: $116 · 2023: $160 · 2024: $171 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113 · Travel and Lodging: $767 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.48 |
| Travel and Lodging | $767.29 |
| Education | $117.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $14,787.43 | 2019-2020 | |
| Inspire Medical Systems, INC. | $1,172.14 | 2024-2025 | Inspire |
| Sunovion Pharmaceuticals INC. | $242.33 | 2019 | |
| Glaxosmithkline, LLC. | $158.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $139.62 | 2019-2024 | Fasenra |
| Harmony Biosciences LLC | $129.06 | 2022-2023 | Wakix |
| Actelion Pharmaceuticals US, INC. | $120.32 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Genentech USA, INC. | $92.04 | 2019 | |
| Amgen INC. | $89.96 | 2022-2025 | Tezspire, Tavneos |
| Genzyme Corporation | $82.23 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.15 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Grifols USA, LLC | $70.71 | 2019-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $60.55 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Resmed Corp | $48.15 | 2025 | |
| Verona Pharma, INC. | $41.81 | 2025 | Ohtuvayre |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $41.66 | 2019-2022 | |
| Abiomed | $38.29 | 2025 | |
| Tactile Systems Technology INC | $35.07 | 2025 | Flexitouch Plus, Nimbl |
| Insmed, INC. | $33.62 | 2020-2025 | |
| 3b Medical, INC. | $30.03 | 2025 | Luna |
| Jazz Pharmaceuticals INC. | $29.95 | 2019-2025 | |
| Allergan, INC. | $29.12 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.64 | 2019 | |
| Merck Sharp & Dohme LLC | $21.76 | 2024 | |
| Astellas Pharma US INC | $17.96 | 2024 | Cresemba |
| Mallinckrodt Hospital Products INC. | $17.20 | 2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $15.47 | 2022 | |
| Lilly USA, LLC | $14.98 | 2025 | Zepbound |
| Electromed, INC. | $14.54 | 2025 | Smartvest |
| Pfizer INC. | $13.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.62 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.60 | 2022 | |
| Circassia INC. | $11.36 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.